InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Selects Lead Synthetic CBD Analogue

July 28, 2021 10:33:53

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has selected a lead synthetic CBD analogue that is expected to move forward in clinical development for both inflammation and pain. According to the update, Sir Marc Feldmann’s (the company’s co-executive chairman and co-founder) laboratory, and 180 Life Sciences’ scientists, as part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), identified the non-psychoactive CBD analogue as a lead molecule in the company’s SCA platform. The analog was selected based on a wide-ranging screen of derivatives of cannabidiol and cannabigerol made by Professor Mechoulam. “We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Prof Raphael Mechoulam, meets all the criteria desirable to advance to clinical development,” said Dr. James Woody, 180 Life Sciences’ CEO. “We look forward to continuing to pursue new therapeutics for one of the world’s largest drivers of disease, inflammation.”

To view the full press release, visit

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary, most advanced platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), which is in the clinic. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.